Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Vera Therapeutics (NASDAQ:VERA) and maintained a price target of $107.
September 16, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Vera Therapeutics, maintaining a $107 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and a high price target by a reputable analyst suggests a positive outlook for Vera Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100